Dr. Morris is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-794-5446
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
Duke University HospitalResidency, Internal Medicine, 2008 - 2011
University of Tennessee Health Science Center College of MedicineClass of 2008
Certifications & Licensure
FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2026
GA State Medical License 2023 - 2026
TN State Medical License 2023 - 2026
TX State Medical License 2012 - 2026
AL State Medical License 2023 - 2025
LA State Medical License 2023 - 2025- Join now to see all
Clinical Trials
- A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 Start of enrollment: 2015 Jul 16
- M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability Start of enrollment: 2018 Mar 07
- Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer Start of enrollment: 2019 Jun 14
Publications & Presentations
PubMed
- The prognostic impact of tumor deposits in colorectal cancer: More than just N1c.Neal Bhutiani, Oliver Peacock, Abhineet Uppal, Chung-Yuan Hu, Brian K Bednarski
Cancer. 2024-12-01 - Epigenome Reprogramming Through H3K27 and H3K4 Trimethylation as a Resistance Mechanism to DNA Methylation Inhibition in BRAFV600E-Mutated Colorectal Cancer.Hey Min Lee, Ajay Kumar Saw, Van K Morris, Stefania Napolitano, Christopher Bristow
Clinical Cancer Research. 2024-11-15 - 1 citationsMolecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival.Mahmoud Yousef, Abdelrahman Yousef, Saikat Chowdhury, Mohammad M Fanaeian, Mark Knafl
JAMA Oncology. 2024-11-01
Journal Articles
- Anti-EGFR Resistant Clones Decay Exponentially After Progression: Implications for Anti-EGFR Re-ChallengeB Kee, N Garg, M J Overman, V K Morris, B Johnson, J Wu, J H Strickler, S Kopetz, X Liu, D S Hong, Annals of Oncology
Lectures
- NRG-GI005 (COBRA): Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
- Are We Moving the Needle in Advanced Colorectal and Anal Cancers?ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
Press Mentions
Gastrointestinal Medical Oncologist and Researcher Driven to Help Patients Live LongerOctober 8th, 2024- MD Anderson Research Highlights: ASCO 2024 Special EditionMay 23rd, 2024
- Timely Surveillance with Chest Imaging May Benefit Colorectal Cancer PatientsOctober 16th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
